--- title: "Co-Diagnostics, Inc. (CODX.US)" type: "Symbol" locale: "en" url: "https://longbridge.com/en/quote/CODX.US.md" symbol: "CODX.US" name: "Co-Diagnostics, Inc." industry: "Health Care Equipment" datetime: "2026-05-19T20:26:47.619Z" locales: - [en](https://longbridge.com/en/quote/CODX.US.md) - [zh-CN](https://longbridge.com/zh-CN/quote/CODX.US.md) - [zh-HK](https://longbridge.com/zh-HK/quote/CODX.US.md) --- # Co-Diagnostics, Inc. (CODX.US) ## Company Overview Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. The company also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, malaria, dengue, human papillomavirus, chikungunya, and Zika virus. | Item | Detail | |------|--------| | Industry | Health Care Equipment | | Exchange | US Market | | Website | [co-dx.com](https://co-dx.com) | ## Key Drivers > *AI-analyzed key factors driving this stock's performance* ## Longbridge Financial Score™: D > *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge* > Updated: 2026-05-19T04:30:12.000Z **Overall: D (0.78)** **Industry**: Health Care Equipment | Metric | Value | |--------|-------| | Industry Ranking | 151 / 183 | | Industry Median | C | | Industry Average | C | - **Style**: Value - Stocks where the company's main business is in a mature stage. - **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns. **Multi Score**: D #### Style Score Score: | Indicator | Value | Rating | |-----------|-------|--------| | Revenue YoY | -79.47% | | | Net Profit YoY | -35.25% | | | P/B Ratio | 0.31 | | | Dividend Ratio | 0.00% | | #### Size Score Score: | Indicator | Value | Rating | |-----------|-------|--------| | Market Cap | 4935377.05 | | | Revenue | 718166.00 | | #### Multi Score Score: D | Indicator | Value | Rating | |-----------|-------|--------| | ROE | -151.66% | E | | Profit Margin | -6753.69% | E | | Gross Margin | -32.76% | E | | Revenue YoY | -79.47% | E | | Net Profit YoY | -35.25% | D | | Total Assets YoY | -61.02% | E | | Net Assets YoY | -66.52% | E | | Cash Flow Margin | 0.00% | D | | OCF YoY | -79.47% | E | | Turnover | 0.02 | E | | Gearing Ratio | 25.38% | B | ```chart-data:radar { "title": "Longbridge Financial Score - Co-Diagnostics, Inc.", "chart_type": "radar", "dimensions": [ { "name": "Style Score", "grade": "", "indicators": [ { "name": "Revenue YoY", "value": "-79.47%", "rating": "" }, { "name": "Net Profit YoY", "value": "-35.25%", "rating": "" }, { "name": "P/B Ratio", "value": "0.31", "rating": "" }, { "name": "Dividend Ratio", "value": "0.00%", "rating": "" } ] }, { "name": "Size Score", "grade": "", "indicators": [ { "name": "Market Cap", "value": "4935377.05", "rating": "" }, { "name": "Revenue", "value": "718166.00", "rating": "" } ] }, { "name": "Multi Score", "grade": "D", "indicators": [ { "name": "ROE", "value": "-151.66%", "rating": "E" }, { "name": "Profit Margin", "value": "-6753.69%", "rating": "E" }, { "name": "Gross Margin", "value": "-32.76%", "rating": "E" }, { "name": "Revenue YoY", "value": "-79.47%", "rating": "E" }, { "name": "Net Profit YoY", "value": "-35.25%", "rating": "D" }, { "name": "Total Assets YoY", "value": "-61.02%", "rating": "E" }, { "name": "Net Assets YoY", "value": "-66.52%", "rating": "E" }, { "name": "Cash Flow Margin", "value": "0.00%", "rating": "D" }, { "name": "OCF YoY", "value": "-79.47%", "rating": "E" }, { "name": "Turnover", "value": "0.02", "rating": "E" }, { "name": "Gearing Ratio", "value": "25.38%", "rating": "B" } ] } ] } ``` ## Valuation Analysis | Metric | Current | Industry Ranking | High | Median | Low | |--------|---------|-----------------|------|--------|-----| | PE (TTM) | -0.10 | 54/183 | - | - | - | | PB | 0.31 | 8/183 | 0.43 | 0.21 | 0.15 | | PS (TTM) | 6.87 | 103/183 | 20.12 | 10.27 | 2.76 | | Dividend Yield | 0.00% | - | - | - | - | ## Peer Comparison | Rank | Name | Profit | Growth | Operation | Security | Cash | Rating | | --- | --- | --- | --- | --- | --- | --- | --- | | 01 | Delcath (DCTH.US) | C | A | B | A | A | A | | 02 | Electromed (ELMD.US) | A | B | A | A | B | A | | 03 | Intuitive Surgical (ISRG.US) | A | B | C | A | B | B | | 04 | Stryker (SYK.US) | A | C | C | C | B | B | | 05 | Boston Scientific (BSX.US) | A | B | C | C | B | B | ## Institutional View ### Analyst Rating Distribution > As of 2026-01-23T05:00:00.000Z Total Analysts: **2** | Rating | Count | Percentage | |--------|-------|-----------| | Hold | 2 | 100% | ### Target Price Forecast | Metric | Price | |--------|-------| | Current Price | 1.97 | | Highest Target | 45.00 | | Lowest Target | 45.00 | ## References - [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/CODX.US/overview.md) - [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/CODX.US/norm.md) - [Related News](https://longbridge.com/en/quote/CODX.US/news.md) - [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/CODX.US/filings.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**